Evaluation of the Effect of Photodynamic Therapy on CAM-Grown Sarcomas

Kerkhoff, Maximilian; Grünewald, Susanne; Schaefer, Christiane; Zöllner, Stefan; Plaumann, Pauline; Busch, Maike; Dünker, Nicole; Ketzer, Julia; Kersting, Josephine; Bauer, Sebastian; Hardes, Jendrik; Streitbürger, Arne; Dirksen, Uta; Hartmann, Wolfgang; Guder, Wiebke

doi:10.3390/bioengineering10040464

Cited by 2 publications

(1 citation statement)

References 38 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In two studies, 3D cellular xenografts obtained from MFS cells (MUG-myx1 and MFS-SN1) were implanted in CAM to test the efficacy of photodynamic therapy for control of local recurrence in soft tissue tumors. In both cases, results demonstrated that photoactivation of the photosensitizer 5-aminolevulinic acid (5-ALA) greatly reduced xenograft volume [69,78].…”

Section: Cell Line-derived Xenograft Cell Line-derived Xenograft In Cammentioning

confidence: 99%

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Lucarelli,

De Vita,

Bellotti

et al. 2023

Cancers

View full text Add to dashboard Cite

Myxofibrosarcoma (MFS) is a malignant soft tissue sarcoma (STS) that originates in the body’s connective tissues. It is characterized by the presence of myxoid (gel-like) and fibrous components and typically affects patients after the fifth decade of life. Considering the ongoing trend of increasing lifespans across many nations, MFS is likely to become the most common musculoskeletal sarcoma in the future. Although MFS patients have a lower risk of developing distant metastases compared with other STS cases, MFS is characterized by a high frequency of local recurrence. Notably, in 40–60% of the patients where the tumor recurs, it does so multiple times. Consequently, patients may undergo multiple local surgeries, removing the risk of potential amputation. Furthermore, because the tumor relapses generally have a higher grade, they exhibit a decreased response to radio and chemotherapy and an increased tendency to form metastases. Thus, a better understanding of MFS is required, and improved therapeutic options must be developed. Historically, preclinical models for other types of tumors have been instrumental in obtaining a better understanding of tumor development and in testing new therapeutic approaches. However, few MFS models are currently available. In this review, we will describe the MFS models available and will provide insights into the advantages and constraints of each model.

show abstract

Section: Cell Line-derived Xenograft Cell Line-derived Xenograft In Cammentioning

confidence: 99%

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Lucarelli,

De Vita,

Bellotti

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

CAM Model: Intriguing Natural Bioreactor for Sustainable Research and Reliable/Versatile Testing

Palumbo,

Sisi,

Checchi

2023

Biology

View full text Add to dashboard Cite

We are witnessing the revival of the CAM model, which has already used been in the past by several researchers studying angiogenesis and anti-cancer drugs and now offers a refined model to fill, in the translational meaning, the gap between in vitro and in vivo studies. It can be used for a wide range of purposes, from testing cytotoxicity, pharmacokinetics, tumorigenesis, and invasion to the action mechanisms of molecules and validation of new materials from tissue engineering research. The CAM model is easy to use, with a fast outcome, and makes experimental research more sustainable since it allows us to replace, reduce, and refine pre-clinical experimentation (“3Rs” rules). This review aims to highlight some unique potential that the CAM-assay presents; in particular, the authors intend to use the CAM model in the future to verify, in a microenvironment comparable to in vivo conditions, albeit simplified, the angiogenic ability of functionalized 3D constructs to be used in regenerative medicine strategies in the recovery of skeletal injuries of critical size (CSD) that do not repair spontaneously. For this purpose, organotypic cultures will be planned on several CAMs set up in temporal sequences, and a sort of organ model for assessing CSD will be utilized in the CAM bioreactor rather than in vivo.

show abstract

Evaluation of the Effect of Photodynamic Therapy on CAM-Grown Sarcomas

Cited by 2 publications

References 38 publications

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

CAM Model: Intriguing Natural Bioreactor for Sustainable Research and Reliable/Versatile Testing

Contact Info

Product

Resources

About